Biotricity Inc. posts 9/30/2025 results via Form 8-K release

Biotricity Inc. reported that it has released its financial results for the period ended September 30, 2025.

Accepted by SEC EDGAR 11/18/2025 - 04:05 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Biotricity Inc. reported that it has released its financial results for the period ended September 30, 2025. The company announced these results through a press release dated November 14, 2025, which is included as Exhibit 99.1. The notice clarifies that this earnings information is being furnished under a current report and is not deemed filed for liability purposes under the securities laws unless specifically incorporated by reference elsewhere.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Biotricity Inc. (BTCY) announce in this 8-K filing?

Biotricity Inc. announced that it issued a press release on November 14, 2025 reporting its financial results for the period ended September 30, 2025, which is attached as Exhibit 99.1.

Which financial period does Biotricity Inc. (BTCY) cover in the announced results?

The reported financial results cover Biotricity Inc.’s performance for the period ended September 30, 2025.

How is the Biotricity Inc. (BTCY) earnings press release treated under securities laws?

The earnings press release furnished in Item 2.02, including Exhibit 99.1, is stated as not deemed filed for purposes of Section 18 of the Exchange Act and is only incorporated by reference into other filings if expressly specified.

Where can investors find the detailed financial results for Biotricity Inc. (BTCY)?

Detailed financial results are contained in Biotricity Inc.’s press release for the period ended September 30, 2025, which is attached to the report as Exhibit 99.1.

Who signed Biotricity Inc.’s November 2025 Form 8-K?

The Form 8-K was signed on behalf of Biotricity Inc. by Waqaas Al-Siddiq, who is identified as the company’s Chief Executive Officer.

What exhibits are included with this Biotricity Inc. (BTCY) Form 8-K?

The report includes Exhibit 99.1, which is the press release announcing financial results, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001630113 0001630113 2025-11-14 2025-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 14, 2025

BIOTRICITY INC.

(Exact name of registrant as specified in its charter)

Nevada		001-40761		30-0983531
(State or Other Jurisdiction of Incorporation or Organization)		(Commission File Number)		(IRS Employer Identification No.)

203 Redwood Shores Parkway, Suite 600

Redwood City, California 94065

(Address of Principal Executive Offices)

(800) 590-4155

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 14, 2025, Biotricity Inc. (the “Company”) issued a press release announcing the Company’s financial results for the period ended September 30, 2025. The press release is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1	Press Release
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 18, 2025

	BIOTRICITY INC.
	By:	/s/ Waqaas Al-Siddiq
		Waqaas Al-Siddiq
		Chief Executive Officer